Please Wait.....
Report
Germany Radiopharmaceuticals Market By Radioisotope (Technetium 99m, Fluorine 18, Iodine I, Gallium 68, Others), By Application (Cancer, Cardiology, Others), By Type (Diagnostic, Therapeutic), By End User (Hospitals and clinics, Medical Imaging centers, Others): Opportunity Analysis and Industry Forecast, 2023-2032
Market Report I 2023-05-01 I 83 Pages I Allied Market Research
Radiopharmaceuticals are drug-producing compounds of contaminated materials that are utilized in medical imaging and also cancer cells treatments. They are carried out intravenously to people for detecting and treating malignant as well as benign growths, cardiovascular diseases, as well as neurological illness. Germany is just one of the leading markets for radiopharmaceuticals in Europe. The nation is taking innovative steps to establish brand-new items, innovations, and solutions to satisfy its radiopharmaceuticals require. The market place for radiopharmaceuticals in Germany is approximated to be valued at around EUR 349 million in 2020, and is approximated to reach around EUR 417 million in 2025, revealing a CAGR of 4.1% during 2020-2025.
In recent years, the demand for radiopharmaceuticals in Germany has actually been gradually increasing due to the increasing frequency of cancer cells, including lung cancer cells. The raising occurrence of cardiovascular diseases, such as cardiac arrest and also stroke, as well as the growing demand for efficient diagnostics and also proper treatment for them, are some of the significant motive power behind the growth of the radiopharmaceuticals market in Germany. Additionally, the government's assistance for performing scientific trials and also its investments in r & d (R&D) activities to create novel drugs as well as techniques that will improve the effectiveness of radiopharmaceuticals is also supplying incentive to the growth of the market.
On the other hand, the absence of experienced personnel for manufacturing and also operating complicated radiopharmaceutical systems, the limited accessibility of radiopharmaceuticals, the high cost of radiopharmaceuticals, as well as the rigorous policies troubled the manufacturing and distribution of radiopharmaceuticals may prevent the growth of the market.
Radiopharmaceuticals have great possible to open up brand-new avenues for clinical diagnosis and also therapy, as they offer specific and also reliable techniques for tracking as well as treating numerous conditions. Innovations in imaging technology as well as the advancement of novel radiolabeled medications are several of the crucial possibilities in the German market. On top of that, with the surge in the number of professional trials to establish much more reliable radiopharmaceuticals as well as capitalize on the expanding demand for customized medicines, the radiopharmaceuticals market in Germany is anticipated to witness a significant surge in development opportunities.
Moreover, the growth of ingenious drug-targeted radiopharmaceuticals will certainly be useful for the market as it will certainly allow a lot more effective individual administration and the delivery of personalized medicines. These trends are anticipated to bring fresh chances for players in the radiopharmaceuticals market in Germany.
Radiopharmaceuticals go through rigorous guidelines. In Germany, these laws are set by different organizations, consisting of the Federal Institute for Drugs as well as Medical Gadget (BfArM); the Federal Office for Radiation Protection (BfS); and also the Technical Standard on Radiopharmacy Therapy, which sets criteria for the production of radiopharmaceuticals as well as their control in Germany. These laws are implemented to make certain a secure and effective production and also professional use of radiopharmaceuticals, hence keeping the standards of high quality as well as continuing to promote security in the medical field.
The Germany radiopharmaceuticals market is fractional by radioisotope (Technetium 99m, Fluorine 18, Iodine I, Gallium 68, Others), by application (Cancer, Cardiology, Others), by kind (Diagnostics, Restorative), as well as by end individual (Healthcare facilities and also clinics, Medical Imaging Centers, Others). Among the sectors, Technetium 99m held the biggest share in the marketplace in 2019, adhered to by Fluorine 18 and Iodine. Technetium 99m is generally utilized for medical imaging applications such as positron discharge tomography and single-photon discharge computed tomography scans, while Fluorine 18 and Iodine are utilized primarily in oncology for the medical diagnosis as well as treatment of cancer cells.
The Germany radiopharmaceuticals market is a fairly combined market, with a couple of huge gamers running in it. The affordable atmosphere on the market is influenced primarily by the bargaining power of distributors as well as purchasers, the danger of new participants, the threat of replacements, and also the intensity of rivalry amongst existing players. Vendors have restricted bargaining power out there, as there are a couple of makers of radiopharmaceuticals and also the costs are very managed. Purchaserson the other hand, have considerable negotiating power due to the visibility of several different choices available for clinical imaging as well as therapy. The danger of brand-new entrants is reduced due to the existence of strict governing framework on the market. The danger of replacements is modest, as radiopharmaceuticals are irreplaceable
Key Benefits For Stakeholders
Enable informed decision-making process and offer market analysis based on current market situation and estimated future trends.
Analyze the key strategies adopted by major market players in Germany radiopharmaceuticals market.
Assess and rank the top factors that are expected to affect the growth of Germany radiopharmaceuticals market.
Top player positioning provides a clear understanding of the present position of market players.
Detailed analysis of the Germany radiopharmaceuticals market segmentation assists to determine the prevailing market opportunities.
Identify key investment pockets for various offerings in the market.
Additional benefits you will get with this purchase are:
- Quarterly Update and* (only available with a corporate license, on listed price)
- 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
- Free Upcoming Version on the Purchase of Five and Enterprise User License.
- 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
- 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
- Free data Pack on the Five and Enterprise User License. (Excel version of the report)
- Free Updated report if the report is 6-12 months old or older.
- 24-hour priority response*
- Free Industry updates and white papers.
Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)
- New Product Development/ Product Matrix of Key Players
- Patient/epidemiology data at country, region, global level
- Regulatory Guidelines
- Additional company profiles with specific to client's interest
- Additional country or region analysis- market size and forecast
- Expanded list for Company Profiles
- Historic market data
- Key player details (including location, contact details, supplier/vendor network etc. in excel format)
- SWOT Analysis
Key Market Segments
By Type
- Diagnostic
- Therapeutic
By End User
- Hospitals and clinics
- Medical Imaging centers
- Others
By Radioisotope
- Fluorine 18
- Iodine I
- Gallium 68
- Others
- Technetium 99m
By Application
- Cancer
- Cardiology
- Others
- Key Market Players
- Advanced Accelerator Applications
- Progenics Pharmaceuticals
- Curium
- BERLIN-CHEMIE AG
- EOS imaging
- Fujirebio Europe
- IDC Basel
- IBA Molecular
- Mallinckrodt Pharmaceuticals
- Nuclear Pharmacy Services GmbH
CHAPTER 1: INTRODUCTION
1.1. Report Description
1.2. Key Market Segments
1.3. Key Benefits to the Stakeholders
1.4. Research Methodology
1.4.1. Primary Research
1.4.2. Secondary Research
1.4.3. Analyst Tools and Models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market Definition and Scope
3.2. Key Findings
3.2.1. Top Impacting Factors
3.2.2. Top Investment Pockets
3.3. Porter's Five Forces Analysis
3.4. Market Dynamics
3.4.1. Drivers
3.4.2. Restraints
3.4.3. Opportunities
3.5. COVID-19 Impact Analysis on the market
CHAPTER 4: GERMANY RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE
4.1. Overview
4.1.1. Market Size and Forecast, By Radioisotope
4.2. Technetium 99m
4.3. Fluorine 18
4.4. Iodine I
4.5. Gallium 68
4.6. Others
CHAPTER 5: GERMANY RADIOPHARMACEUTICALS MARKET, BY APPLICATION
5.1. Overview
5.1.1. Market Size and Forecast, By Application
5.2. Cancer
5.3. Cardiology
5.4. Others
CHAPTER 6: GERMANY RADIOPHARMACEUTICALS MARKET, BY TYPE
6.1. Overview
6.1.1. Market Size and Forecast, By Type
6.2. Diagnostic
6.3. Therapeutic
CHAPTER 7: GERMANY RADIOPHARMACEUTICALS MARKET, BY END USER
7.1. Overview
7.1.1. Market Size and Forecast, By End User
7.2. Hospitals and clinics
7.3. Medical Imaging centers
7.4. Others
CHAPTER 8: COMPETITIVE LANDSCAPE
8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Top player positioning, 2022
CHAPTER 9: COMPANY PROFILES
9.1. Company 1
9.1.1. Company overview
9.1.2. Key Executives
9.1.3. Company snapshot
9.1.4. Operating business segments
9.1.5. Product portfolio
9.1.6. Business performance
9.1.7. Key strategic moves and developments
9.2. Company 2
9.2.1. Company overview
9.2.2. Key Executives
9.2.3. Company snapshot
9.2.4. Operating business segments
9.2.5. Product portfolio
9.2.6. Business performance
9.2.7. Key strategic moves and developments
9.3. Company 3
9.3.1. Company overview
9.3.2. Key Executives
9.3.3. Company snapshot
9.3.4. Operating business segments
9.3.5. Product portfolio
9.3.6. Business performance
9.3.7. Key strategic moves and developments
9.4. Company 4
9.4.1. Company overview
9.4.2. Key Executives
9.4.3. Company snapshot
9.4.4. Operating business segments
9.4.5. Product portfolio
9.4.6. Business performance
9.4.7. Key strategic moves and developments
9.5. Company 5
9.5.1. Company overview
9.5.2. Key Executives
9.5.3. Company snapshot
9.5.4. Operating business segments
9.5.5. Product portfolio
9.5.6. Business performance
9.5.7. Key strategic moves and developments
9.6. Company 6
9.6.1. Company overview
9.6.2. Key Executives
9.6.3. Company snapshot
9.6.4. Operating business segments
9.6.5. Product portfolio
9.6.6. Business performance
9.6.7. Key strategic moves and developments
9.7. Company 7
9.7.1. Company overview
9.7.2. Key Executives
9.7.3. Company snapshot
9.7.4. Operating business segments
9.7.5. Product portfolio
9.7.6. Business performance
9.7.7. Key strategic moves and developments
9.8. Company 8
9.8.1. Company overview
9.8.2. Key Executives
9.8.3. Company snapshot
9.8.4. Operating business segments
9.8.5. Product portfolio
9.8.6. Business performance
9.8.7. Key strategic moves and developments
9.9. Company 9
9.9.1. Company overview
9.9.2. Key Executives
9.9.3. Company snapshot
9.9.4. Operating business segments
9.9.5. Product portfolio
9.9.6. Business performance
9.9.7. Key strategic moves and developments
9.10. Company 10
9.10.1. Company overview
9.10.2. Key Executives
9.10.3. Company snapshot
9.10.4. Operating business segments
9.10.5. Product portfolio
9.10.6. Business performance
9.10.7. Key strategic moves and developments
LIST OF TABLES
TABLE 01. GERMANY RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE, 2022-2032 ($MILLION)
TABLE 02. GERMANY RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 03. GERMANY RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 04. GERMANY RADIOPHARMACEUTICALS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 05. COMPANY 1: KEY EXECUTIVES
TABLE 06. COMPANY 1: COMPANY SNAPSHOT
TABLE 07. COMPANY 1: OPERATING SEGMENTS
TABLE 08. COMPANY 1: PRODUCT PORTFOLIO
TABLE 09. COMPANY 1: KEY STRATERGIES
TABLE 10. COMPANY 2: KEY EXECUTIVES
TABLE 11. COMPANY 2: COMPANY SNAPSHOT
TABLE 12. COMPANY 2: OPERATING SEGMENTS
TABLE 13. COMPANY 2: PRODUCT PORTFOLIO
TABLE 14. COMPANY 2: KEY STRATERGIES
TABLE 15. COMPANY 3: KEY EXECUTIVES
TABLE 16. COMPANY 3: COMPANY SNAPSHOT
TABLE 17. COMPANY 3: OPERATING SEGMENTS
TABLE 18. COMPANY 3: PRODUCT PORTFOLIO
TABLE 19. COMPANY 3: KEY STRATERGIES
TABLE 20. COMPANY 4: KEY EXECUTIVES
TABLE 21. COMPANY 4: COMPANY SNAPSHOT
TABLE 22. COMPANY 4: OPERATING SEGMENTS
TABLE 23. COMPANY 4: PRODUCT PORTFOLIO
TABLE 24. COMPANY 4: KEY STRATERGIES
TABLE 25. COMPANY 5: KEY EXECUTIVES
TABLE 26. COMPANY 5: COMPANY SNAPSHOT
TABLE 27. COMPANY 5: OPERATING SEGMENTS
TABLE 28. COMPANY 5: PRODUCT PORTFOLIO
TABLE 29. COMPANY 5: KEY STRATERGIES
TABLE 30. COMPANY 6: KEY EXECUTIVES
TABLE 31. COMPANY 6: COMPANY SNAPSHOT
TABLE 32. COMPANY 6: OPERATING SEGMENTS
TABLE 33. COMPANY 6: PRODUCT PORTFOLIO
TABLE 34. COMPANY 6: KEY STRATERGIES
TABLE 35. COMPANY 7: KEY EXECUTIVES
TABLE 36. COMPANY 7: COMPANY SNAPSHOT
TABLE 37. COMPANY 7: OPERATING SEGMENTS
TABLE 38. COMPANY 7: PRODUCT PORTFOLIO
TABLE 39. COMPANY 7: KEY STRATERGIES
TABLE 40. COMPANY 8: KEY EXECUTIVES
TABLE 41. COMPANY 8: COMPANY SNAPSHOT
TABLE 42. COMPANY 8: OPERATING SEGMENTS
TABLE 43. COMPANY 8: PRODUCT PORTFOLIO
TABLE 44. COMPANY 8: KEY STRATERGIES
TABLE 45. COMPANY 9: KEY EXECUTIVES
TABLE 46. COMPANY 9: COMPANY SNAPSHOT
TABLE 47. COMPANY 9: OPERATING SEGMENTS
TABLE 48. COMPANY 9: PRODUCT PORTFOLIO
TABLE 49. COMPANY 9: KEY STRATERGIES
TABLE 50. COMPANY 10: KEY EXECUTIVES
TABLE 51. COMPANY 10: COMPANY SNAPSHOT
TABLE 52. COMPANY 10: OPERATING SEGMENTS
TABLE 53. COMPANY 10: PRODUCT PORTFOLIO
TABLE 54. COMPANY 10: KEY STRATERGIES
LIST OF FIGURES
FIGURE 01. GERMANY RADIOPHARMACEUTICALS MARKET, 2022-2032
FIGURE 02. SEGMENTATION OF GERMANY RADIOPHARMACEUTICALS MARKET, 2022-2032
FIGURE 03. TOP INVESTMENT POCKETS IN GERMANY RADIOPHARMACEUTICALS MARKET (2023-2032)
FIGURE 04. PORTER FIVE-1
FIGURE 05. PORTER FIVE-2
FIGURE 06. PORTER FIVE-3
FIGURE 07. PORTER FIVE-4
FIGURE 08. PORTER FIVE-5
FIGURE 09. DRIVERS, RESTRAINTS AND OPPORTUNITIES: GERMANY RADIOPHARMACEUTICALS MARKET
FIGURE 10. GERMANY RADIOPHARMACEUTICALS MARKET,BY RADIOISOTOPE, 2022 ($MILLION)
FIGURE 11. GERMANY RADIOPHARMACEUTICALS MARKET,BY APPLICATION, 2022 ($MILLION)
FIGURE 12. GERMANY RADIOPHARMACEUTICALS MARKET,BY TYPE, 2022 ($MILLION)
FIGURE 13. GERMANY RADIOPHARMACEUTICALS MARKET,BY END USER, 2022 ($MILLION)
FIGURE 14. TOP WINNING STRATEGIES, BY YEAR
FIGURE 15. TOP WINNING STRATEGIES, BY DEVELOPMENT
FIGURE 16. TOP WINNING STRATEGIES, BY COMPANY
FIGURE 17. PRODUCT MAPPING OF TOP 10 PLAYERS
FIGURE 18. COMPETITIVE DASHBOARD
FIGURE 19. COMPETITIVE HEATMAP: GERMANY RADIOPHARMACEUTICALS MARKET
FIGURE 20. TOP PLAYER POSITIONING, 2022
FIGURE 21. COMPANY 1: NET SALES, 2020-2022*($MILLION)
FIGURE 22. COMPANY 1: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 23. COMPANY 1: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
FIGURE 24. COMPANY 2: NET SALES, 2020-2022*($MILLION)
FIGURE 25. COMPANY 2: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 26. COMPANY 2: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
FIGURE 27. COMPANY 3: NET SALES, 2020-2022*($MILLION)
FIGURE 28. COMPANY 3: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 29. COMPANY 3: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
FIGURE 30. COMPANY 4: NET SALES, 2020-2022*($MILLION)
FIGURE 31. COMPANY 4: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 32. COMPANY 4: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
FIGURE 33. COMPANY 5: NET SALES, 2020-2022*($MILLION)
FIGURE 34. COMPANY 5: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 35. COMPANY 5: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
FIGURE 36. COMPANY 6: NET SALES, 2020-2022*($MILLION)
FIGURE 37. COMPANY 6: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 38. COMPANY 6: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
FIGURE 39. COMPANY 7: NET SALES, 2020-2022*($MILLION)
FIGURE 40. COMPANY 7: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 41. COMPANY 7: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
FIGURE 42. COMPANY 8: NET SALES, 2020-2022*($MILLION)
FIGURE 43. COMPANY 8: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 44. COMPANY 8: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
FIGURE 45. COMPANY 9: NET SALES, 2020-2022*($MILLION)
FIGURE 46. COMPANY 9: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 47. COMPANY 9: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
FIGURE 48. COMPANY 10: NET SALES, 2020-2022*($MILLION)
FIGURE 49. COMPANY 10: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 50. COMPANY 10: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security